Israel Englander’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Israel Englander’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-174,994	Closed	-$157K	–	7190
2022 Q4	$157K	Buy	174,994 +112,878	+182%	+$327K	﹤0.01%	5418
2022 Q3	$373K	Buy	+62,116	New	+$352K	﹤0.01%	5206
2021 Q4	–	Sell	-60,108	Closed	-$280K	–	7603
2021 Q3	$280K	Sell	60,108 -81,675	-58%	-$433K	﹤0.01%	5868
2021 Q2	$1M	Buy	141,783 +126,853	+850%	+$684K	﹤0.01%	4669
2021 Q1	$88K	Buy	+14,930	New	+$90.4K	﹤0.01%	5709
2020 Q4	–	Sell	-45,926	Closed	-$179	–	5715
2020 Q3	$179	Buy	45,926 +38,736	+539%	+$778K	﹤0.01%	4100
2020 Q2	$207K	Buy	+7,190	New	+$166K	﹤0.01%	3832
2019 Q4	–	Sell	-35,038	Closed	-$525K	–	4755
2019 Q3	$525K	Buy	+35,038	New	+$544K	﹤0.01%	3228

Other funds holding STSA

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return

Israel Englander's STSA Position: Q1 2023 in Review

Israel Englander sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q1 2023, closing a stake of 174,994 shares — an estimated $157K sold.

Israel Englander first reported a position in STSA in Q3 2019 and held it in 8 quarters. The position peaked at $1M in Q2 2021. 31 funds tracked by Wall St. Rank hold STSA as of Q1 2023.

Israel Englander reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Israel Englander sold 174,994 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $157K.
Israel Englander first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 8 quarters.
Israel Englander's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $1M in Q2 2021.
31 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.